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Abstract Clinical resistance to chemotherapy in acute
myeloid leukemia (AML) is associated with the expression
of the multidrug resistance (MDR) proteins P-glycoprotein,
encoded by the MDR1/ABCB1 gene, multidrug resistant-
related protein (MRP/ABCC1), the lung resistance-related
protein (LRP), or major vault protein (MVP), and the breast
cancer resistance protein (BCRP/ABCG2). The clinical
value of MDR1, MRP1, LRP/MVP, and BCRP messenger
RNA (mRNA) expression was prospectively studied in 154
newly diagnosed AML patients ≥60 years who were treated
in a multicenter, randomized phase 3 trial. Expression of
MDR1 and BCRP showed a negative whereas MRP1 and
LRP showed a positive correlation with high white blood
cell count (respectively, p<0.05, p<0.001, p<0.001 and p<
0.001). Higher BCRP mRNA was associated with second-
ary AML (p<0.05). MDR1 and BCRP mRNA were highly
significantly associated (p<0.001), as were MRP1 and LRP
mRNA (p<0.001) expression. Univariate regression analy-
ses revealed that CD34 expression, increasing MDR1
mRNA as well as MDR1/BCRP coexpression, were asso-
ciated with a lower complete response (CR) rate and with
worse event-free survival and overall survival. When
adjusted for other prognostic actors, only CD34-related
MDR1/BCRP coexpression remained significantly associated
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Introduction
Clinical resistance to chemotherapy in acute myeloid
leukemia (AML) is often associated with the expression
of (membrane) transport-associated multidrug resistance
(MDR) proteins. Expression of P-glycoprotein (P-gp),
encoded by the MDR1 gene, is an independent adverse
prognostic factor for response and survival in de novo
AML [1–4]. Moreover, it has been shown that besides P-
gp, also the MDR-related protein (MRP1/ABCC1) and the
lung resistance-related protein (LRP), also designated as
the major vault protein (MVP), are expressed in AML.
However, the prognostic significance of the latter resis-
tance proteins has not been settled [3, 5–7]. Some years
ago, a new drug resistant protein, i.e., the breast cancer
resistance protein (BCRP/ABCG2), which is the equiva-
lent of the mitoxantrone (MXT) resistant protein and the
placental ABC transporter (ABCP), was found to be
expressed in AML [8–13]. The precise role of either
resistance proteins among poor risk AML such as in
patients of older age has not been established. This study
prospectively investigated the relevance of MDR1, MRP1,
LRP,a n dBCRP messenger RNA (mRNA) expression in
combination with known prognostic characteristics like
CD34 expression, white blood cell (WBC) count, and
secondary AML as possible denominators of response and
survival in patients with AML aged 60+ who were treated
in the same clinical trial.
Patients and methods
Patients
A group of 154 patients with AML aged 60 years or older
were included in the present study. All patients were
enrolled between May 1997 and February 1999 in an
international, multigroup, randomized phase 3 trial per-
formed under auspices of the Dutch–Belgian Hemato-
Oncology Cooperative Group and the UK Medical
Research Council [14]. In that trial, 419 eligible white
patients ≥60 years with previously untreated de novo and
secondary AML (M0–M2 and M4–M7 according to the
French–American–British [FAB] classification [15]) were
randomized to receive two cycles of induction chemother-
apy consisting of daunorubicin (DNR) and cytarabine (ara-
C) with or without the P-gp inhibitor PSC-833 (Valspodar,
Amdray®; Novartis Pharma, Basle, Switzerland). Patients
in both arms in complete remission after these two cycles
were to receive one consolidation consisting of ara-C,
MXT, and etoposide. Inclusion criteria, clinical character-
istics, treatment, and outcome of the phase 3 trial have
been previously reported [14].
Bone marrow (BM) aspirates had been collected at
diagnosis for the analysis of P-gp function and expression,
as described previously [14]. Selection of patients for our
study was based on availability of sufficient purified AML
blast samples in our tissue bank, which was the case for 154
patients.
This study was approved by the ethics committees of the
participating institutions and was conducted in accordance
with the Declaration of Helsinki. Written informed consent
was obtained from all patients before randomization.
Methods
BM aspirates were obtained in heparinized tubes. Mono-
nuclear BM cells were collected by Ficoll Hypaque density
gradient centrifugation (density 1.077 g/m
3; Pharmacia,
Uppsala, Sweden). To obtain purified samples with more
than 85% of blasts, T-cell depletion and adherence
depletion was performed as previously described [16].
Cells were cryopreserved in Dulbecco modified Eagle
medium (DMEM; Gibco, Paisley, UK) supplemented with
10% dimethyl sulfoxide (Merck, Darmstadt, Germany) and
20% fetal calf serum (FCS; Gibco) and stored in liquid
nitrogen. On the day of the experiments, BM cells were
thawed. Cells were washed and resuspended in DMEM
supplemented with 10% FCS. Before RNA and DNA
isolation, cells were washed with phosphate-buffered saline
(Gibco).
MDR1, MRP1, LRP, and BCRP mRNA analysis
The drug resistance proteins were analyzed using the
methods that we previously reported [11]. In brief, total
RNA was isolated using the TRISOLV™ extraction as
described by the manufacturer (Biotecx, Houston, TX).
RNA was aliquoted and stored at −80°C. RNA samples
were analyzed for RNA integrity by gel electrophoresis.
cDNA was synthesized by the use of the TaqMan Reverse
Transcription Reagents (Applied Biosystems, Foster City,
CA), diluted, aliquoted, and stored at −80°C. Quantitative
RT-PCR was used to measure the mRNA expression levels
of MDR1, MRP1, LRP, and BCRP by Taqman-chemistry on
an ABI PRISM 7700 sequence detector (Applied Biosys-
tems) using two endogenous reference genes, i.e., glycer-
aldehyde-3-phosphate dehydrogenase and porphobilinogen
deaminase.
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The clinical endpoints have been defined previously [14].
In brief, complete response (CR) was defined as a
normocellular BM with <5% blasts, no Auer rods, and no
evidence of extramedullary involvement. Because data on
peripheral blood recovery within 60 days were not always
available, they were not considered as a criterium for CR.
Patients who relapsed or died within 28 days after CR were
considered as not having achieved a CR. Event-free
survival (EFS) was calculated from the date of randomiza-
tion until no CR on induction therapy, relapse after CR, or
death in CR, whichever came first. Patients who did not
reach CR were considered failure for EFS at 1 day after
randomization. Disease-free survival (DFS) was determined
for all patients who achieved CR on induction therapy and
was calculated from the date of CR until relapse or death,
whichever came first. Overall survival (OS) was measured
from randomization until death from any cause. Patients
who were still alive at the date of last contact were then
censored.
Statistical analysis
The original phase 3 trial had been designed to detect with
a power of 80% an increase in 2-year EFS from 9.5% in the
control arm (without PSC-833) to 18% in the PSC-833 arm
(two-sided significance level α=0.05) and included 419
eligible patients.
mRNA data were obtained from a subset of 154 patients
with sufficient BM samples in our tissue bank available for
analysis. Baseline parameters of interest were MDR1,
MRP1, LRP,a n dBCRP mRNA expression. Clinical
endpoints were CR rate, EFS, DFS, and OS.
Baseline characteristics of patients with or without
mRNA expression data available were compared using the
Fisher exact test or the Pearson χ2 test in case of discrete
variables, whichever appropriate, or the Wilcoxon rank-
sum test in case of continuous variables. The association
between patient baseline characteristics and mRNA ex-
pression levels was analyzed using the Pearson χ2 test of
the Spearman rank correlation test, whichever was
appropriate. The prognostic value of mRNA levels with
respect to CR rate was determined using logistic regres-
sion [17] whereas the impact of MDR1, MRP1, LRP,a n d
BCRP on EFS, DFS, and OS was analyzed with Cox
regression analysis [18]. For this purpose, the natural
logarithm of the mRNA expression levels of the four
resistance genes were included in the analyses because of
the very skewed distribution of the original mRNA levels.
In addition, the outcome of patients with coexpression of
MDR1 and BCRP was evaluated to confirm the poor
prognosis of AML with MDR1/BCRP coexpression
reported by Benderra et al. [19] in patients with a median
age of 45 years or older. These patients were defined as
having mRNA levels of these two drug resistance genes
equal to or higher than the median. Their outcome was
compared to the other patients with at least one of the
MDR1 and BCRP mRNA expression levels below the
median. Logistic regression and Cox regression analyses
were performed unadjusted, as well as adjusted for other
prognostic factors, i.e., secondary AML, natural logarithm
of WBC count, square root of percentage CD34
+ cells, and
cytogenetic risk (favorable/intermediate versus unfavor-
able versus unknown), as well as for treatment arm in the
phase 3 trial, as about half of the patients had been
randomized to receive PSC-833 in addition to their
chemotherapy. Kaplan–Meier curves [20] were generated
to illustrate survival and were compared using the log-rank
test [21]. All reported p values are two-sided and, in view
of the exploratory nature of these analyses, were calculat-
ed without adjustment for multiple testing. p values≤0.05
were considered statistically significant.
Results
In the phase 3 trial, a total of 419 untreated patients with
AML aged 60 years and older were randomized to receive
two induction cycles with or without PSC-833. As reported,
no difference was found between both treatment arms as
regards CR rate (54% in the PSC-833 arm versus 48% in
the control arm, p=0.22), 5-year EFS (7 versus 8%, p=
0.53) nor DFS (13 versus 17%, p=0.06) and OS (10% in
both arms, p=0.52) [14]. We previously reported the role of
functional MDR1 expression with respect to clinical
outcome in these patients.
In 154/419 of the patients, sufficient BM cells were
available in our tissue bank to investigate the mRNA
expression level of the drug resistance genes MDR1, MRP1,
LRP,a n dBCRP. This subgroup consisted of a representative
group according to age, gender, CD34 expression, cytoge-
netics, and FAB classification (Table 1). In this test group, a
higher WBC count at diagnosis was observed than in the
other 265 patients, and relatively more patients had been
randomized to the PSC-833 arm (57 versus 45%, p=0.02).
There was no significant difference in the levels of MDR1,
MRP1, LRP,n o rBCRP mRNA expression between the two
treatment arms (data not shown). The CR rate and survival
endpoints were also similar in both patient groups (Table 1).
However, patients with mRNA data in the PSC-833 arm had
a higher CR rate (61 versus 40%, p=0.02), whereas this was
54 versus 48% (p=0.22) in all 419 patients.
The mRNA expression levels of the resistance genes
were not significantly associated with the age of the
patients (Table 2). MRP1 and LRP expression showed a
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associations of MDR1 and BCRP with WBC count were
observed. A significant positive association was found
between CD34 and MDR1 and also with BCRP mRNA
expression. No significant correlation was found between
MRP1 nor LRP, and CD34 expression (Table 2). Interest-
ingly, secondary AML cases had a significantly higher
expression of BCRP (p<0.05) and lower MRP1 and LRP
levels (both p<0.01, Table 2). In the vast majority of our
patients, also P-gp efflux and expression data were
available. Function and expression data and MDR1 mRNA
expression levels were highly correlated (p<0.001), which
was published recently [22].
In this cohort of patients of higher age with AML,
MDR1 and BCRP were highly associated (p<0.001), just
as were MRP1 and LRP mRNA (p<0.001; Fig. 1). A
negative association was found between BCRP and MRP1
and between BCRP and LRP (both p<0.001; Fig. 1). The
40 patients with coexpression of BCRP and MDR1 had
significantly higher CD34 expression (median 39.5%
[range 0.1–97.7%] versus 25.9% [range 0.1–97.9%]; p=
0.001) and a lower WBC count (median 4.5 [range 0.8–
300]×10
9/l versus 28.1 [range 0.1–389]×10
9/l; p<0.001).
No significant correlation of MDR1, BCRP,o rc o e x p r e s -
sion of MDR1 and BCRP was found with unfavorable
cytogenetics (p=0.4; Table 2).
Table 1 Comparison between patients with or without data available for expression of the drug resistance genes
Drug resistance genes evaluated
Yes N (%) No N (%) Total N (%) p
Number of patients 154 265 419
Patient characteristics
Median age, (range) 67 (60–85) 68 (58–85) 67 (58–85) 0.52
Sex 0.26
Male 86 (56) 163 (62) 249 (59)
Female 68 (44) 102 (38) 170 (41)
Secondary AML 31 (20) 73 (28) 104 (25) 0.09
Median WBC count (×10
9/l; range) 19.1 (0.1–389) 5.6 (0.5–300) 8.9 (0.1–389) 0.001
N 146 243 389
Median % CD34
+, (range) 32.5 (0.1–97.9) 29.7 (0.1–93.7) 30.3 (0.1–97.9) 0.50
N 152 157 309
Cytogenetic risk classification
a 0.12
Favorable 3 (3) 2 (1) 5 (2)
Intermediate 90 (80) 132 (73) 222 (76)
Unfavorable 19 (17) 47 (26) 66 (23)
No data 42 (n.i.) 84 (n.i.) 126 (n.i.)
Treatment arm randomized 0.02
DNR/ara-C 66 (43) 145 (55) 211 (50)
DNR/ara-C +PSC-833 88 (57) 120 (45) 208 (50)
Treatment outcome
CR rate, % (95% CI) 52 (44–60) 50 (44–56) 51 (46–56) 0.73
EFS, % (95% CI) 0.72
1 year 23 (17–30) 23 (18–28) 23 (19–27)
5 years 9 (5–14) 7 (4–11) 8 (5–11)
DFS, % (95% CI) 0.81
1 year 38 (27–48) 39 (31–48) 39 (32–45)
5 years 17 (10–26) 14 (9–21) 15 (11–21)
OS, % (95% CI) 0.31
1 year 42 (34–50) 41 (35–46) 41 (36–46)
5 years 14 (9–20) 8 (5–12) 10 (7–14)
The results indicate that, apart from WBC count, there are no differences between the two subgroups.
N number of patients with data (if not available for all patients); n.i. not included when calculating percentages
aClassification of cytogenetic abnormalities only for 293 patients with successful cytogenetics. Favorable risk: t(8;21), inv(16) or t(16;16).
Unfavorable risk: the presence of monosomies or deletions of chromosomes 5 or 7, abnormalities of the long arm of chromosome 3(q21;q26), t
(6;9), abnormalities involving the long arm of chromosome 11 (11q23), or complex cytogenetic abnormalities (defined as at least three unrelated
cytogenetic abnormalities in one clone). Patients who did not meet the criteria for favorable or unfavorable risk were classified as intermediate
risk [14].
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genes, their expression was evaluated with regard to CR
rate and survival data, respectively. The median follow-up
of the 25 patients still alive was 58 months (range, 1–
80 months). Univariate logistic regression analysis showed
that higher MDR1 mRNA expression predicted for a lower
CR rate (log[MDR1]: odds ratio [OR]=0.75, 95% confi-
dence interval [CI] 0.61–0.93, p=0.009), whereas MRP1,
LRP, and BCRP mRNA were not associated with CR
(Fig. 1). MDR1 expression was also associated with a
worse EFS (log[MDR1]: hazard ratio [HR]=1.14, 95% CI
1.03–1.27, p=0.01) and OS (log[MDR1]: HR=1.16, 95%
CI 1.05–1.29, p=0.004). Similar results were also obtained
for MDR1/BCRP coexpression (Table 3; Fig. 2). When the
analyses were performed with adjustment for other prog-
nostic factors, as described in the “Statistical analysis”, only
MDR1/BCRP mRNA coexpression remained significantly
associated with a lower CR rate (OR=0.37, 95% CI 0.15–
0.91, p=0.03), whereas a trend was observed for worse EFS
(Table 3). On the other hand, higher CD34 expression was
significantly associated with a lower CR rate (square root
[CD34]: OR=0.86, 95% CI 0.76–0.98, p=0.02) and with
worse EFS (HR=1.12, 95% CI 1.06–1.19, p<0.001), DFS
(HR=1.19, 95% CI 1.09–1.30, p<0.001), and OS (HR=
1.17, 95% CI=1.10–1.25, p<0.001).
Discussion
This is the first comprehensive analysis of the effect of the
major classical MDR genes in a cohort of elderly patients
with AML homogeneously treated in a prospective clinical
trial [14]. A wide range of expression of the various
resistance genes was observed, consistent with previous
studies and with comparable median values [9–11, 23]. Our
results show that MRP1, LRP, and BCRP are not associated
with CR rate or survival endpoints in patients with AML
Fig. 1 Association between MDR1, MRP1, LRP, and BCRP mRNA
expression levels. Each dot represents the expression of two drug
resistance genes in one patient. The Spearman rank correlation
coefficient has been calculated, along with the corresponding p value.
Both the x- and y-axis have a logarithmic scale trim(X)* indicates that
the 2.5% smallest and largest values of X have been shrinked; r,
Spearman rank correlation coefficient; and p, p value. The results
show a significant positive correlation between MDR1 and BCRP
mRNA expression as illustrated by the p value and correlation
coefficient. In addition, MRP1 and LRP are highly associated. BCRP
shows a negative correlation with MRP1 and LRP
Table 2 Association between clinical patient characteristics and the mRNA expression of the four drug resistance genes and MDR1/BCRP
coexpression
mRNA expression of
MDR1 MRP1 LRP BCRP MDR1/BCRP coexpression
Characteristic
Age 0.15 −0.01 −0.09 0.09 0.07
(153) (153) (153) (137) (147)
Secondary AML 0.06 −0.22** −0.21** 0.19* 0.12
(153) (153) (153) (137) (147)
WBC count −0.17* 0.28*** 0.36*** −0.36*** −0.35***
(145) (145) (145) (131) (139)
CD34
+ 0.54*** 0.14 −0.08 0.17* 0.27**
(151) (151) (151) (135) (145)
Unfavorable 0.11 −0.05 −0.23* 0.13 0.10
Cytogenetic risk (111) (111) (111) (98) (106)
Unfavorable cytogenetic risk was defined by the presence of monosomies or deletions of chromosomes 5 or 7, abnormalities of the long arm of
chromosome 3(q21;q6), t(6;9), abnormalities involving the long arm of chromosome 11 (11q23), or complex cytogenetic abnormalities (defined
as at least three unrelated cytogenetic abnormalities in one clone)
Each cell displays the Spearman rank correlation coefficient between two variables and, between brackets, the number of patients with both
variables available.
*p<0.05; **p<0.01; ***p<0.001
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of the expression of these genes is limited in this patient
population. This study confirms previous reports, which
showed the unique prognostic role of MDR1 expression—
which was however highly correlated with CD34 expres-
sion—in drug resistance in elderly AML (Table 3), in
Table 3 Prognostic value of drug resistance gene expression w.r.t. CR rate, EFS, DFS from CR, and OS
CR rate EFS DFS OS
OR 95% CI p HR 95% CI p HR 95% CI p HR 95% CI p
MDR1
Univariate 0.75 0.61–0.93 0.009 1.14 1.03–1.27 0.01 1.13 0.97–1.30 0.11 1.16 1.05–1.29 0.004
Adjusted 0.77 0.58–1.03 0.08 1.05 0.91–1.21 0.48 0.95 0.77–1.18 0.67 1.00 0.87–1.16 0.97
MRP1
Univariate 1.06 0.83–1.35 0.63 1.02 0.90–1.15 0.79 1.07 0.89–1.29 0.47 1.11 0.97–1.26 0.12
Adjusted 1.22 0.90–1.66 0.20 1.00 0.87–1.15 0.98 1.12 0.92–1.37 0.26 1.05 0.91–1.21 0.54
LRP
Univariate 1.16 0.94–1.43 0.16 0.95 0.86–1.06 0.36 0.98 0.84–1.14 0.79 0.97 0.87–1.08 0.60
Adjusted 1.22 0.93–1.61 0.15 0.99 0.87–1.12 0.83 1.06 0.89–1.27 0.52 0.98 0.86–1.12 0.78
BCRP
Univariate 0.84 0.66–1.06 0.14 1.04 0.91–1.18 0.58 0.95 0.77–1.16 0.60 0.96 0.84–1.10 0.58
Adjusted 0.79 0.59–1.06 0.12 0.99 0.86–1.14 0.92 0.84 0.66–1.06 0.14 0.90 0.77–1.05 0.19
MDR1/BCRP
co-expression
Univariate 0.38 0.18–0.80 0.01 1.63 1.11–2.37 0.01 1.65 0.90–3.01 0.11 1.47 1.00–2.16 0.05
Adjusted 0.37 0.15–0.92 0.03 1.53 0.98–2.38 0.06 1.37 0.67–2.82 0.39 1.16 0.74–1.83 0.51
Results of logistic (for CR rate) and Cox regression (for survival) analyses, either univariate (=unadjusted) or adjusted for treatment arm,
secondary AML, WBC count (natural logarithm), % CD34
+ (square root), and cytogenetic risk (favorable/intermediate versus unfavorable
versus unknown), are shown for each of the four drug resistance genes MDR1, MRP1, LRP, and BCRP (natural logarithm of mRNA expression
levels) and for MDR1/BCRP co-expression.
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Fig. 2 Survival of elderly AML patients with and without coexpression of MDR1 and BCRP mRNA. a Event-free survival, b disease-free
survival, c overall survival. pos indicates patients with coexpression of MDR1 and BCRP; and other, patients without coexpression
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AML, which has shown conflicting results, whereas
currently, LRP is no longer thought to be important for
clinical drug resistance [4, 5, 7, 24–27]. Recently, two
studies in, respectively, 40 and 31 adult AML patients
showed no effect of BCRP gene expression on CR rate,
whereas OS was lower in patients with the highest BCRP
expression [10, 23]. Damiani et al. [28] showed that BCRP
expression did not influence achievement of complete
remission in AML patients with a median age of 53 years
and normal karyotype, however, BCRP expression was
associated with higher relapse rate. In 59 children with de
novo AML, a higher BCRP expression was observed in
patients who did not reach CR, but this was not translated
in poorer survival [29]. Benderra et al. [19] indicated that
BCRP gene expression was an adverse prognostic factor for
CR in a group of 149 relatively younger adult AML
patients but only in patients treated with DNR and MXT
and not with idarubicin. In our cohort of elderly AML
patients who were all treated with DNR, whereas MXT was
given as consolidation therapy after reaching CR, a
significant correlation of BCRP mRNA expression with
lower CR rate could not be shown.
OurstudyconfirmsthatBCRP and MDR1 are coexpressed
in AML patients with higher age as has been suggested
previously from studies in smaller groups of relatively
younger AML patients [9–11, 28]. Until now, only two
studies have evaluated the clinical value of coexpression of
MDR1 and BCRP in a sufficient number, although relatively
younger adult AML patients [19, 28]. Benderra et al. [19]
showed that CR rate was only 45% in the patients with
coexpression of BCRP and MDR1 (+/+) in comparison with
66% in the MDR1/BCRP−/+ and +/−group and 90% in the
MDR1/BCRP−/−group (p=0.003). Moreover, a significantly
lower DFS and OS were found in the MDR1/BCRP+/
+group. Damiani et al. [28] found a trend towards a higher
relapse rate in the small group of BCRP+/MDR1+patients,
indicating that this represents a robust resistant AML
phenotype, consistent with our findings in elderly AML.
The recent finding that BCRP and MDR1 expression was
mainly found in the most resistant group of AML, using
gene expression profiling, underscores the role of these drug
resistance genes in AML [30].
However, this study shows, that the prominent prognos-
tic role of CD34 expression in elderly AML should be
emphasized, as higher CD34 expression was adversely
associated with all clinical endpoints. MDR1 and BCRP but
not MRP1 and LRP mRNA expression were found to be
associated with high CD34 expression in these elderly
AML patients, which may explain why MDR1 was no
longer significant for CR rate, EFS, and OS when adjusted
for other prognostic variables including CD34. In the past,
MDR1 expression has been linked to the CD34-positive
hematopoietic stem cell compartment of the leukemia
subtype. In two other studies in younger AML patients,
no overexpression (on mRNA and protein level) of BCRP
in the CD34-positive blast population of clinical AML
samples was found [13, 19]. In contrast, earlier studies in
mice demonstrated high levels of BCRP and MDR1
expression in normal hematopoietic stem cells [31–34].
Previously, BCRP expression in subsets of stem cells has
been reported, indicating that high BCRP expression may
exist in CD34
+/CD38
− cells or in CD34
+/CD33
−cells [12,
35]. The differential expression of BCRP and MDR1 in
specific subsets of hematopoietic stem cells is consistent
with the side population phenotype as proposed by Goodell
et al. [36] who claim that BCRP expression can be
separated from those expressing the other ABC proteins.
This would suggest that BCRP is expressed in even less
differentiated hematopoietic stem cells than MDR1 [19]. In
our study in AML, these immature subsets could not be
separately investigated, however, the unique BCRP/MDR1
+/+subgroup of patients reflects an immature leukemic cell
type that has a very resistant phenotype in vivo, illustrated
by a low CR rate and poor outcome (Table 3; Fig. 2).
This is the first study in which a correlation was found
between secondary AML and a high expression of BCRP
mRNA but not the other resistance proteins. In addition to
our previous report that BCRP is frequently upregulated in
patients with AML at relapse, we now demonstrate that
expression of BCRP is representative of secondary AML,
which is especially observed in elderly patients [11, 29].
Recently, Ross [37] suggested that MDR modifiers may be
of benefit for patients with multiple dysplastic features. This
may suggest that BCRP is upregulated in diseases in which
exposure to xenobiotics during life plays an etiologic role.
We conclude that coexpression of CD34-related coex-
pression of MDR1 and BCRP reflects a clinically resistant
subgroup of elderly AML. In this age group, only BCRP is
correlated with secondary AML. As such, the development
of new treatment strategies for elderly AML patients may
focus on modulation of drug resistance targeting both
BCRP and MDR1.
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